Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A9 | P48067 | 20/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3705074 | 0.85 | SLC6A9 (0.59) | SLC6A9 | |
| SCHEMBL3705077 | 0.85 | SLC6A9 (0.59) | SLC6A9 | |
| SCHEMBL4242856 | 0.84 | SLC6A9 (1.00) | SLC6A9 | |
| SCHEMBL4174261 | 0.84 | SLC6A9 (1.00) | SLC6A9 | |
| SCHEMBL4246371 | 0.84 | SLC6A9 (1.00) | SLC6A9 | |
| SCHEMBL4335143 | 0.81 | SLC6A9 (0.51) | SLC6A9 | |
| SCHEMBL786955 | 0.81 | SLC6A9 (0.66) | SLC6A9 | |
| SCHEMBL786901 | 0.80 | SLC6A9 (0.66) | SLC6A9 | |
| SCHEMBL786894 | 0.80 | SLC6A9 (0.68) | SLC6A9 | |
| SCHEMBL3708032 | 0.80 | SLC6A9 (0.51) | SLC6A9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090030033-A1 | Novel Compounds 894 | ASTRAZENECA AB (SE) | 2009-01-29 | — | — | US | disclosed |
| US-20090030033-A1 | Novel Compounds 894 | ASTRAZENECA AB (SE) | 2009-01-29 | — | — | US | disclosed |
| WO-2009013535-A1 | 2-AZABICYCLO(2.2.2)OCTANE DERIVATIVES AS MODULATORS OF THE GLYCINE TRANSPORTER I RECEPTOR | ASTRAZENECA AB (SE) | 2009-01-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090030033-A1 | Novel Compounds 894 | AZI2, TPMT, AMPD2 | SLC6A9 4382/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.